Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Variant||ETV6 - NTRK1|
|Protein Effect||gain of function - predicted|
|Gene Variant Descriptions||ETV6-NTRK1 results in the fusion of ETV6 and NTRK1 (PMID: 26884591). ETV6-NTRK1 has not been biochemically characterized, but is sensitive to Trk inhibition (PMID: 26884591), and therefore, is predicted to result in a gain of function.|
|Associated Drug Resistance|
|Molecular Profile||Protein Effect||Treatment Approaches|
|ETV6 - NTRK1||gain of function - predicted||Larotrectinib|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ETV6 - NTRK1||Advanced Solid Tumor||predicted - sensitive||Entrectinib||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells expressing ETV6-NTRK1 were sensitive to Rozlytrek (entrectinib) as demonstrated by reduced proliferation relative to cells expressing an empty vector in culture (PMID: 26884591).||26884591|
|ETV6 - NTRK1||Advanced Solid Tumor||sensitive||DS6051b||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells expressing ETV6-NTRK1 were sensitive to treatment with DS6051b in culture, demonstrating cell growth inhibition (PMID: 31399568).||31399568|